Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay

Cancer Biology and Therapy

Volumn 3, Issue 5, 2004, Pages 453-457

  Coyne, Robert S ^a,d   McDonald, Heather B ^b,e   Edgemon, Keith ^c   Brody, Lawrence C ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Center for Language and Brain   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d NATIONAL SCIENCE FOUNDATION   (United States)

^e AAAS   (United States)

Author keywords

BRCA1 protein; Breast neoplasms; Saccharomyces cerevisiae

Indexed keywords

AMINO ACID; BRCA1 PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; ASSAY; CANCER RISK; CARBOXY TERMINAL SEQUENCE; MISSENSE MUTATION; MUTATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SPECIES CONSERVATION; STRUCTURE ANALYSIS; YEAST; BREAST TUMOR; CANCER STEM CELL; CLASSIFICATION; FEMALE; GENETIC VARIABILITY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PHENOTYPE; SACCHAROMYCES CEREVISIAE; TRANS-ACTIVATION (GENETICS); TUMOR STEM CELLS; VARIATION (GENETICS);

EID: 21644480379     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.5.809     Document Type: Article

References (51)

1. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52:678-701.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-5.
3. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:265-71.
4. Rosen EM, Fan S, Goldberg ID. BRCA1 and prostate cancer. Cancer Invest 2001; 19:396-412.
5. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res 1994; 54:6069-72.
6. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992; 2:128-31.
7. Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, et al. BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci USA 1999; 96:11866-71.
8. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997; 389:187-90.
9. Breast Cancer Information Core Database. http://research.nhgri.nih.gov/ bic/
10. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996; 8:8-18.
11. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8:399-404.
12. Carter RF. BRCA1, BRCA2 and breast cancer: A concise clinical review. Clin Invest Med 2001; 24:147-57.
13. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: Mechanisms of inactivation and implications for management of patients. Lancet 2002; 360:1007-14.
14. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349:1505-10.
15. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77:697-709.
16. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90:1138-45.
17. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
18. Hedenfalk IA. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures. J Natl Cancer Inst 2002; 94:960-1.
19. Monteiro AN. BRCA1: Exploring the links to transcription. Trends Biochem Sci 2000; 25:469-74.
20. Kerr P, Ashworth A. New complexities for BRCA1 and BRCA2. Curr Biol 2001; 11:R668-76.
21. Scully R, Puget N. BRCA1 and BRCA2 in hereditary breast cancer. Biochimie 2002; 84:95-102.
22. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114:3591-8.
23. Walter NAR, Messier W. Direct submission. Genbank 1999; Accession number: AAG43492.
24. Szabo CI, Wagner LA, Francisco LV, Roach JC, Argonza R, King MC, et al. Human, canine and murine BRCA1 genes: Sequence comparison among species. Hum Mol Genet 1996; 5:1289-98.
25. Bennett LM, Brownlee HA, Hagavik S, Wiseman RW. Sequence analysis of the rat Brca1 homolog and its promoter region. Mamm Genome 1999; 10:19-25.
26. Krum SA, Lane TF. Bos taurus breast and ovarian cancer susceptibility protein (BRCA1) mRNA. Genbank 2002;Accession number: NP_848668.
27. Orelli BJ, Logsdon Jr JM, Bishop DK. Nine novel conserved motifs in BRCA1 identified by the chicken orthologue. Oncogene 2001; 20:4433-8.
28. Joukov V, Chen J, Fox EA, Green JB, Livingston DM. Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc Natl Acad Sci USA 2001; 98:12078-83.
29. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: An evolutionary approach. Proc Natl Acad Sci USA 2003; 100:1151-6.
30. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 2001; 8:833-7.
31. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 2001; 8:838-42.
32. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002; 16:583-93.
33. Williams RS, Glover JN. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem 2003; 278:2630-5.
34. Ekblad CM, Wilkinson HR, Schymkowitz JW, Rousseau F, Freund SM, Itzhaki LS. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1. J Mol Biol 2002; 320:431-42.
35. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4:1093-9.
36. Ye Q, Hu YF, Zhong H, Nye AC, Belmont AS, Li R. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J Cell Biol 2001; 155:911-21.
37. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996; 382:678-9.
38. Hayes F, Cayanan C, Barilla D, Monteiro AN. Functional assay for BRCA1: Mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res 2000; 60:2411-8.
39. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996; 93:13595-9.
40. Monteiro AN, August A, Hanafusa H. Common BRCA1 variants and transcriptional activation. Am J Hum Genet 1997; 61:761-2.
41. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001; 10:353-60.
42. Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD. Human BRCA1 inhibits growth in yeast: Potential use in diagnostic testing. Proc Natl Acad Sci USA 1997; 94:5820-5.
43. Kleiman FE, Manley JL. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 1999; 285:1576-9.
44. Miyake T, Hu YF, Yu DS, Li R. A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling. J Biol Chem 2000; 275:40169-73.
45. Monteiro AN, Humphrey JS. Yeast-based assays for detection and characterization of mutations in BRCA1. Breast Disease 1998; 10:61-70.
46. Vallejo AN, Pogulis RJ, Pease LR. Mutagenesis and synthesis of novel recombinant genes using PCR. In: Dieffenbach CW, Dveksler GS, eds. PCR Primer: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Press, 1995; 603-612.
47. Vojtek AB, Hollenberg SM. Ras-Raf interaction: Two-hybrid analysis. Methods Enzymol 1995; 255:331-42.
48. Chen CF, Yang B. One-step method for yeast transformation. Curr. Genet 1992; 21:83-84.
49. Mirkovic N, Marti-Renom MA, Weber BL, et al. Structure-based assessment of missense mutations in human BRCA1: Implications for breast and ovarian cancer predisposition. Cancer Res 2004; In press.
50. Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS. The BRCA1 C-terminal domain: Structure and function. Mutat Res 2000; 460:319-32.
51. Zhang X, Morera S, Bates PA, Whitehead PC, Coffer AI, Hainbucher K, Nash RA, Sternberg MJ, Lindahl T, Freemont PS. Structure of an XRCC1 BRCT domain: A new protein-protein interaction module. EMBO J 1998; 17:6404-11.